Compared with placebo , BI @ significantly reduced nasal eosinophil values ( P < @ for all doses ) , significantly inhibited nasal inflammatory cytokine levels ( IL-@ and eotaxin , P < @ ; @ mg twice daily ) , and induced a dose-related reduction in ex vivo prostaglandin D@-mediated eosinophil shape change .